ANGLE PLC (LON:AGL) (OTCQX:ANPCY) has said its liquid biopsy system provides a “straightforward and scalable approach” to analysing and assessing treatment options for men with advanced prostate cancer.
That was the conclusion of associate professor Amir Goldkorn, whose team at the University of Southern California, used ANGLE’s Parsortix device as part of its workflow to decide which drugs or drug combinations to give patients.
Partsortix harvests the tell-tale signs of cancer called circulating tumour cells (CTCs) so that they can then be assessed. It offers an alternative to physical biopsies, which are invasive and painful, and antibody-based methods of capturing of cells.
The ANGLE technology was deployed in a process called transcriptomic profiling. This is the method by which cancer cells are analysed to identify how the patient's cancer is developing and evading the immune system. It allows decisions to be made as to which drug treatments may be most effective for that patient at that time.
Standard tissue biopsy reflects only a single metastatic site at a single point in time, whereas CTCs harvested using Parsortix allows an analysis of cells from potentially multiple sites.
“This approach enables personalised medicine and addresses the major problem of identifying the right drug at the right time as most drugs only work for a proportion of patients and a one size fits all approach is limited in its effectiveness,” ANGLE.
Other advantages of using Parsortix included the high cell enrichment levels; that samples required minimal manipulation; cells were free of antibodies or magnetic beads; allowed rapid, flexible use.
"University of Southern California's workflow using the Parsortix system is a significant step forward as it demonstrates a simple, effective way to utilise the harvested CTCs for gene expression analysis to advise drug selection decisions and to provide a dynamic analysis of the effectiveness of treatment,” Andrew Newland, ANGLE’s chief executive said in a statement.
“We believe the applicability of the workflow will not be limited to prostate cancer and may extend to most, if not all, solid tumour cancer types."